Google has confirmed it is testing ads for "certain pharmaceutical products," including prescription drugs, inside AI Mode and AI Overviews, with the test limited to the U.S. and underway as of this month. A Google spokesperson told Adweek the company "recently expanded to include certain pharmaceutical products" within these AI surfaces.

The full statement Google sent Adweek: "We're testing standard text and Shopping ads in AI Mode and AI Overviews, which we recently expanded to include certain pharmaceutical products."

That's the confirmed part. Google said it directly. Everything else so far is tool-signal territory at best — I could not spot a single pharmaceutical ad in AI Overviews or AI Mode myself, and there's no public screenshot evidence circulating yet. If you've seen one in the wild, that's genuinely notable.

What exactly is Google testing?

Per Adweek's reporting, pharmaceutical advertisers can now run two standard ad formats inside the AI surfaces:

• Standard text ads
• Shopping ads

Both formats appear in sections labeled "Sponsored" — the same disclosure convention Google already uses for ads embedded in AI Overviews since it began monetizing those surfaces.

The test covers prescription drugs, not just over-the-counter products, according to the Google spokesperson who spoke with Adweek. That's the detail that matters for compliance teams.

Did Google change its pharma ads policy?

No — and this is where the speculation needs separating from the statement. When I asked Google directly, I was told there were no recent policy changes governing pharmaceutical advertising. The pharmaceutical industry remains one of Google's most heavily restricted ad categories (healthcare and medicines policies that dictate which drugs can be promoted, by whom, and in which countries).

The last pharma ads policy updates I can trace are March 2026 and October 2025, plus some regional adjustments in specific countries over the past year. Nothing new on that front.

What actually happened is narrower: Google is already testing text and Shopping ads broadly across AI Mode and AI Overviews, and it widened the scope of that existing test to include pharma inventory. Same policy rulebook, expanded test surface.

Why this matters for advertisers and publishers

For pharmaceutical marketers, this opens a new placement in Google's fastest-evolving surfaces — one that sits above the traditional ten blue links and increasingly above standard Shopping results. U.S.-only for now, which tracks with how Google stages restricted-category rollouts.

For health publishers and comparison sites, the calculus is different. If AI Overviews and AI Mode begin carrying sponsored pharma units, the ad-supported answer layer competes more directly with organic content that currently occupies those spaces. Health is already one of the verticals most exposed to AI Overviews summarizing queries instead of sending clicks to specialized sites.

For regulators, prescription drug promotion inside generative AI answers is uncharted compliance territory — the FDA's direct-to-consumer advertising rules were written for display and TV, not conversational interfaces.

What to watch next

Monitor for the first confirmed "Sponsored" pharmaceutical placements in live AI Overviews and AI Mode queries — none have been documented publicly yet — plus any country expansion beyond the U.S. and whether Google formalizes the format once testing concludes.